CA2738930C - Procede d'inhibition d'une activite procoagulante induite par des biomateriaux utilisant des inhibiteurs de complements - Google Patents

Procede d'inhibition d'une activite procoagulante induite par des biomateriaux utilisant des inhibiteurs de complements Download PDF

Info

Publication number
CA2738930C
CA2738930C CA2738930A CA2738930A CA2738930C CA 2738930 C CA2738930 C CA 2738930C CA 2738930 A CA2738930 A CA 2738930A CA 2738930 A CA2738930 A CA 2738930A CA 2738930 C CA2738930 C CA 2738930C
Authority
CA
Canada
Prior art keywords
inhibitor
blood
biomaterial
complement
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2738930A
Other languages
English (en)
Other versions
CA2738930A1 (fr
Inventor
John D. Lambris
Konstantinos Ritis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of CA2738930A1 publication Critical patent/CA2738930A1/fr
Application granted granted Critical
Publication of CA2738930C publication Critical patent/CA2738930C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Abstract

La présente invention concerne des procédés destinés à réduire ou à éliminer une activité procoagulante induite par des biomatériaux dans le sang soumis à un traitement extracorporel qui expose le sang au biomatériau. Les procédés comprennent le traitement du sang, ou du biomatériau extracorporel, ou des deux, par un inhibiteur du complément afin dinhiber la formation de facteurs tissulaires induits par les C5a/C5aR dans le sang.
CA2738930A 2008-09-30 2009-09-29 Procede d'inhibition d'une activite procoagulante induite par des biomateriaux utilisant des inhibiteurs de complements Active CA2738930C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10145308P 2008-09-30 2008-09-30
US61/101,453 2008-09-30
PCT/US2009/058745 WO2010039690A1 (fr) 2008-09-30 2009-09-29 Procédé d’inhibition d’une activité procoagulante induite par des biomatériaux utilisant des inhibiteurs de compléments

Publications (2)

Publication Number Publication Date
CA2738930A1 CA2738930A1 (fr) 2010-04-08
CA2738930C true CA2738930C (fr) 2021-08-17

Family

ID=42073834

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2738930A Active CA2738930C (fr) 2008-09-30 2009-09-29 Procede d'inhibition d'une activite procoagulante induite par des biomateriaux utilisant des inhibiteurs de complements

Country Status (5)

Country Link
US (1) US8445190B2 (fr)
EP (1) EP2340028B1 (fr)
AU (1) AU2009298684B2 (fr)
CA (1) CA2738930C (fr)
WO (1) WO2010039690A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2698166T3 (pl) 2006-10-10 2016-03-31 Regenesance B V Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
WO2010039690A1 (fr) * 2008-09-30 2010-04-08 The Trustees Of The University Of Pennsylvania Procédé d’inhibition d’une activité procoagulante induite par des biomatériaux utilisant des inhibiteurs de compléments
UY34403A (es) 2011-10-21 2013-05-31 Takeda Pharmaceutical Preparación de liberación sostenida
EP2886140A1 (fr) * 2013-12-17 2015-06-24 University of Limerick Appareil pour le traitement extracorporel du sang
UA124734C2 (uk) 2016-06-14 2021-11-10 Рідженерон Фармасьютікалз, Інк. Антитіло проти с5 і його застосування
JP2021506241A (ja) 2017-12-13 2021-02-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｃ５抗体組み合わせ物およびその使用
KR20220066287A (ko) * 2019-08-27 2022-05-24 제트피 에스피브이 3 케이/에스 콤프스타틴 유사체 및 이의 의약 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6319897B1 (en) 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
AU2006202394A1 (en) * 1997-08-26 2006-06-29 Abgenix, Inc. A process for inhibiting complement activation via the alternative pathway
WO1999013899A1 (fr) * 1997-09-17 1999-03-25 Trustees Of The University Of Pennsylvania Peptides et peptidomimetiques inhibant l'activation du complement
WO1999044625A1 (fr) * 1998-03-03 1999-09-10 John Hopkins University Inhibiteur d'enzymes de complement, derive du virus de la variole (spice), proteines liees au spice et methode d'inhibition de l'activation du complement
JP2003532698A (ja) * 2000-05-10 2003-11-05 プリンストン ユニバーシティ 細菌の増殖および病理発生を調節するための化合物ならびに方法
AUPR833401A0 (en) 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
US7491530B2 (en) 2001-12-18 2009-02-17 Whitehead Institute For Biomedical Research Fusion partner cells and uses thereof
SI1549333T1 (sl) 2002-09-20 2012-02-29 Univ Pennsylvania Analogi kompstatina z izboljĺ ano aktivnostjo
US7959919B2 (en) 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
PT1960422E (pt) 2005-11-28 2012-08-16 Univ Pennsylvania Análogos de compstatina potentes
EP2979729A3 (fr) * 2007-02-05 2016-05-11 Apellis Pharmaceuticals, Inc. Analogues de compstatin pour le treatment de conditions inflammatoires du systeme respiratoire
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
WO2010030789A1 (fr) * 2008-09-10 2010-03-18 Novelmed Therapeutics, Inc. Dispositif et procédé pour l'inhibition de l'activation du complément
WO2010039690A1 (fr) * 2008-09-30 2010-04-08 The Trustees Of The University Of Pennsylvania Procédé d’inhibition d’une activité procoagulante induite par des biomatériaux utilisant des inhibiteurs de compléments

Also Published As

Publication number Publication date
EP2340028A4 (fr) 2013-07-10
US8445190B2 (en) 2013-05-21
WO2010039690A1 (fr) 2010-04-08
US20110269113A1 (en) 2011-11-03
CA2738930A1 (fr) 2010-04-08
EP2340028B1 (fr) 2018-06-27
AU2009298684A1 (en) 2010-04-08
AU2009298684B2 (en) 2015-11-19
EP2340028A1 (fr) 2011-07-06

Similar Documents

Publication Publication Date Title
CA2738930C (fr) Procede d'inhibition d'une activite procoagulante induite par des biomateriaux utilisant des inhibiteurs de complements
Jourde-Chiche et al. Endothelium structure and function in kidney health and disease
Frantzeskaki et al. Immunothrombosis in acute respiratory distress syndrome: cross talks between inflammation and coagulation
JP7397037B2 (ja) Ｍａｓｐ－２依存性補体活性化に関連した状態を治療するための方法
Vassalli et al. The pathogenic role of the coagulation process in rabbit Masugi nephritis
CN107638565B (zh) 用于治疗与masp-2依赖性补体活化相关的状况的方法
Nymo et al. Cholesterol crystal-induced endothelial cell activation is complement-dependent and mediated by TNF
WO2012166611A2 (fr) Procédés de traitement et de prévention d'une toxicité net dérivée des neutrophiles et d'une thrombose
WO2011106635A1 (fr) Traitement de la sepsie utilisant des inhibiteurs du complément
M Risitano et al. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3
CN117398458A (zh) 用于治疗与masp-2依赖性补体活化相关的病况的方法
TW202402809A (zh) 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
JP2014517750A (ja) 循環血中の可溶性ウロキナーゼ受容体の低減
JP2019525954A (ja) 敗血症の処置のために用いられるシラスタチン
US20210179717A1 (en) Antibodies against mac-1
RU2714112C2 (ru) Терапевтическая APAC-молекула, содержащая гепарин, конъюгированный с белком плазмы крови
Ward et al. Complement System
JP2009539757A (ja) 血栓溶解活性を有するａｄａｍｔｓ１３含有組成物
US20240156906A1 (en) Anticoagulant proteins and their use for treating diseases associated with the activation of neutrophils
Blatt Role of complement regulatory proteins properdin and factor H in platelet/granulocyte aggregate formation
Hardersen Biocompatibility in low-density lipoprotein apheresis and plasma separation
WO2023152291A1 (fr) Méthodes et composition pharmaceutique pour le traitement de troubles thrombotiques
櫻井健太郎 Role for Neutrophil Extracellular Traps (NETs) and Platelet Aggregation in Early Sepsis-induced Hepatic Dysfunction
Asare et al. Complement Blocking Therapeutic Strategies: A Prospective Approach for the Treatment of Cardiovascular Diseases
Pol Pathogenic role of complement in renal ischemia/reperfusion injury

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140903